CB1R-5-HT2AR-HET functionality in ON cells. (A and B) cells were obtained from healthy subjects who do not use cannabis (HC/nc), healthy subjects who use cannabis (HC/c), schizophrenia patients who do not smoke cannabis (SCZ/nc), and schizophrenia patients who use cannabis (SCZ/c). (A) cAMP production (B) pERK activation *P < .05,**P < .01,***P < .001 vs basal values; +P < .05, ++P < .01, +++P < .001 vs WIN or DOI treatment; #P < .05, ##P < .01, ###P < .001 vs HC/nc. (C–F) ON cells obtained from healthy subjects non-cannabis users (HC/nc) (C and D) and from healthy subjects cannabis users (HC/c) (E and F) treated in vitro with vehicle (VEH), aripiprazole (ARP), haloperidol (HAL), or clozapine (CLZ) during 12 days. (C) cAMP production in HC/nc, (D) pERK activation in HC/nc. (E) cAMP production in HC/c. (F) pERK activation in HC/c. *P < .05, **P < .01, ***P < .001 vs basal values; + P < .05, ++P < .01, +++P < .001 vs WIN or DOI treatment and ##P < .01, ###P < .001 vs the VEH group. Data are mean+SEM. ANOVA values for each panel are shown in supplementary table 3.